New pneumonia vaccine shows promise in early trial
NCT ID NCT05092386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new 13-valent pneumococcal conjugate vaccine in 310 healthy volunteers ranging from 6-week-old infants to adults up to 49 years old. The goal was to check the vaccine's safety and how well it triggers the immune system to fight pneumococcal bacteria, which can cause pneumonia and other serious infections. Results will help decide if larger studies are warranted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Center for Diseases Control and Prevention
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Study tracks pneumococcal infections in adults to sharpen vaccine strategies
- Text message nudge could save thousands from pneumonia
- Vaccine Follow-Up: how long does protection last in babies?
- French study tracks pneumococcal infections in kids after vaccine rollout
- Are hidden immune defects causing your recurring infections? new study investigates.
- New vaccine aims to shield infants from deadly pneumonia